Feeds:
Posts
Comments

Posts Tagged ‘Short-course androgen suppression therapy’

JULY 27: URO TODAY: A combination approach to hormone and radiation treatment for men with localised but high risk prostate cancer works better than so-called mono-therapy, a new study has found. READ MORE>

Men treated with external beam radiotherapy and brachytherapy, short-course androgen suppression therapy with a luteinizing hormone-releasing hormone (LHRH) agonist plus an anti-androgen, have decreased prostate cancer-specific mortality compared with mono-therapy with an LHRH agonist, the researchers report.

NEW PROSTATE CANCER INFOLINK: Another study (of about 200 patients) in Japan found combined androgen blockade with an LHRH) agonist + bicalutamide 80 mg had a small, marginally significant overall survival benefit compared to an LHRH agonist + a placebo (ie, LHRH agonist monotherapy) at a median follow-up of 5.2 years. READ MORE>

Read Full Post »

MAY 16: NEW PROSTATE CANCER INFO-LINK:  The results of at least 15 prostate cancer-related studies will be presented at the upcoming annual meeting of the American Society for Clinical Oncology in Orlando, Florida, at the end of May. READ MORE>

Read Full Post »